Warfarin dosing by genotype did not improve time in therapeutic range.

The article focuses on a research related to the development of pharmacogenetic and clinical algorithms for warfarin dosing by genotype as of March 2014. Topics discussed include a personalized approach to clinical management by pharmacogenetics due to the increasing ability to determine genotypes, the impact of polymorphisms of the cytochrome P-450 system on vitamin K antagonist (VAK) and treatment of venous thromboembolism (VTE).